HER2 Support Group Forums - View Single Post - NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the grow

'lizbeth · 10-10-2013, 10:45 AM

http://www.novartisoncology.com/rese...n/pipeline.jsp

BEZ235 is in Phase I/II clinical trials in the pipeline at NovartisOncology.

There are 50 open trials for breast cancer with Novartis products:

http://clinicaltrials.gov/ct2/result...=Open&no_unk=Y

10-10-2013, 10:45 AM	#2
'lizbeth Senior Member Join Date: Apr 2008 Location: Sunny San Diego Posts: 2,214	Re: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the http://www.novartisoncology.com/rese...n/pipeline.jsp BEZ235 is in Phase I/II clinical trials in the pipeline at NovartisOncology. There are 50 open trials for breast cancer with Novartis products: http://clinicaltrials.gov/ct2/result...=Open&no_unk=Y